Barry Z. Bazian

Barry has represented major stakeholders in Chapter 11 bankruptcy cases and proceedings, including the following:

• Omega Therapeutics, representing the DIP lender and stalking horse successful purchaser of substantially all of the assets of Omega Therapeutics, a clinical-stage biotechnology company, under Section 363 of the Bankruptcy Code
• Eiger BioPharmaceuticals, representing purchaser of certain commercial and pipeline assets of Eiger BioPharmaceuticals, a commercial-stage biotechnology company, under Section 363 of the Bankruptcy Code
• Ambri, representing commercial battery technology company as debtor-in-possession in its Chapter 11 case and successful sale of its assets
• ContraFect Corporation, representing a purchaser of substantially all intellectual property assets of ContraFect Corporation, a clinical-stage biotechnology company, under Section 363 of the Bankruptcy Code
• Clarus Therapeutics, representing the specialty pharmaceutical company as debtor-in-possession in its Chapter 11 case and successful sale of its assets
• PhaseBio Pharmaceuticals, representing a purchaser of assets of PhaseBio Pharmaceuticals under Section 363 of the Bankruptcy Code
• Purdue Pharma, representing Teva Pharmaceuticals in Purdue’s Chapter 11 proceedings
• Proteus Digital Health, representing the developer of digital medicine technologies as debtor-in-possession in its Chapter 11 case and successful sale of its assets
• Gibson Brands, representing the iconic guitar manufacturer as debtor-in-possession in its successful restructuring of approximately $500 million of funded debt obligations through a Chapter 11 plan
• Aegerion Pharmaceuticals, representing the parent company and substantial creditor of a rare drug biopharmaceutical company in connection with the Chapter 11 restructuring of over $400 million of liabilities
• Sears Holdings Corporation, representing various vendors and landlords
• Toys R Us, representing various vendors and landlords
• The Rockport Company, representing the stalking horse successful purchaser of substantially all of the assets of The Rockport Company under Section 363 of the Bankruptcy Code
• East Orange General Hospital, representing the not-for-profit hospital as debtor-in-possession in its Chapter 11 case, resulting in its successful sale and the confirmation of a Chapter 11 plan*
• Official Committees of Unsecured Creditors in numerous Chapter 11 cases, including those of Novan, Noranda Aluminum, Gander Mountain, CST Industries, Unilife Corporation, Aquion Energy, Golden County Foods and Ultimate Nutrition*

*Denotes experience prior to joining Goodwin.

Barry has special expertise in royalty-based financings, including sales of traditional royalty and synthetic royalty interests, and product development financings. Barry has represented numerous leading investors and companies in this space, including:

• Royalty Pharma in its synthetic royalty financing of up to $300 million to Zenas BioPharma to support Zenas BioPharma’s obexelimab development program for IgG4-RD and other autoimmune diseases
• Royalty Pharma in its $2 billion funding arrangement with Revolution Medicines, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and up to $750 million in senior secured debt, all to support Revolution Medicines’ plans for global development and commercialization of daraxonrasib and its pipeline programs for patients with RAS-addicted cancers
• Royalty Pharma in its up to $1 billion strategic funding collaborations with Cytokinetics to support the commercialization of aficamten, the commercial launch of omecamtiv mecarbil and the further development of aficamten
• Royalty Pharma in its acquisition of a synthetic royalty on net sales of Emalex Biosciences’ ecopipam for $50 million plus up to $44 million in milestones
• Royalty Pharma in its acquisition of additional royalties on Roche’s Evrysdi for $1.0 billion upfront, with options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date
• Royalty Pharma in its acquisition of a synthetic royalty on US net sales of Ferring’s Adstiladrin® for up to $500 million comprised of an upfront payment of $300 million and a $200 million milestone payment
• Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), on its royalty financing agreement with Healthcare Royalty (HCRx) for up to $115 million
• Abingworth, the life sciences franchise of global investment firm Carlyle, in its strategic development funding agreement with Teva for up to $150 million to offset Teva’s ICS/SABA (TEV-‘248) program costs
• Abingworth in its non-dilutive financing of Pathalys to support the late-stage development of upacicalcet, amounting to $150 million in combination with Pathalys’ concurrent Series A financing
• R-Bridge Healthcare Fund, an affiliate of CBC Group, in its $60 million loan to Paratek Pharmaceuticals, backed by royalties on sales of omadacycline in greater China and a revenue interest in U.S. sales of Nuzyra
• R-Bridge Healthcare Fund in its $40 million loan to Trevena, backed by royalties on sales of oliceridine in greater China and a revenue interest in US sales of Olinvyk
• DRI Capital in its acquisition of MacroGenics’ royalties on sales of Tzield for $100 million upfront and milestone payments of up to $100 million in total
• Avadel Pharmaceutics plc in a royalty financing agreement with RTW Investments to provide up to a $75 million of funding to support the potential commercialization of LUMRYZ™ 
• GLS Capital in its development and litigation funding transaction with a leading generic, specialty pharmaceutical company
• Royalty Pharma in its purchase of certain revenue streams from Biocryst Pharmaceuticals